Pacemaker syndrome epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{RT}} | {{CMG}}; {{AE}} {{RT}} | ||
== Overview == | |||
==Epidemiology== | ==Epidemiology== | ||
| Line 9: | Line 10: | ||
*The wide range of reported incidence is likely attributable to two factors which are the criteria used to define pacemaker syndrome and the therapy used to resolve that diagnosis.<ref name="pmid16943933">{{cite journal |author=Farmer DM, Estes NA, Link MS |title=New concepts in pacemaker syndrome |journal=[[Indian Pacing and Electrophysiology Journal]] |volume=4 |issue=4 |pages=195–200 |year=2004 |pmid=16943933 |pmc=1502063 |doi=|url=http://www.ipej.org/4/195 |issn= |accessdate=2009-06-19}}</ref> | *The wide range of reported incidence is likely attributable to two factors which are the criteria used to define pacemaker syndrome and the therapy used to resolve that diagnosis.<ref name="pmid16943933">{{cite journal |author=Farmer DM, Estes NA, Link MS |title=New concepts in pacemaker syndrome |journal=[[Indian Pacing and Electrophysiology Journal]] |volume=4 |issue=4 |pages=195–200 |year=2004 |pmid=16943933 |pmc=1502063 |doi=|url=http://www.ipej.org/4/195 |issn= |accessdate=2009-06-19}}</ref> | ||
<br /> | |||
===Incidence=== | |||
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide. | |||
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide. | |||
===Prevalence=== | |||
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide. | |||
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide. | |||
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually. | |||
===Case-fatality rate/Mortality rate=== | |||
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%. | |||
*The case-fatality rate/mortality rate of [disease name] is approximately [number range]. | |||
===Age=== | |||
*Patients of all age groups may develop [disease name]. | |||
* The incidence of [disease name] increases with age; the median age at diagnosis is [#] years. | |||
*[Disease name] commonly affects individuals younger than/older than [number of years] years of age. | |||
*[Chronic disease name] is usually first diagnosed among [age group]. | |||
*[Acute disease name] commonly affects [age group]. | |||
=== Race=== | |||
*There is no racial predilection to [disease name]. | |||
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name]. | |||
===Gender=== | |||
*[Disease name] affects men and women equally. | |||
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1. | |||
===Region=== | |||
*The majority of [disease name] cases are reported in [geographical region]. | |||
*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2]. | |||
===Developed Countries=== | |||
===Developing Countries=== | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 22:22, 13 April 2020
|
Pacemaker syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pacemaker syndrome epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Pacemaker syndrome epidemiology and demographics |
|
Pacemaker syndrome epidemiology and demographics in the news |
|
Risk calculators and risk factors for Pacemaker syndrome epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]
Overview
Epidemiology
- The incidence of pacemaker syndrome varies from 2%[1] to 83%.[2] [3]
- The wide range of reported incidence is likely attributable to two factors which are the criteria used to define pacemaker syndrome and the therapy used to resolve that diagnosis.[3]
Incidence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
Prevalence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Case-fatality rate/Mortality rate
- In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
- The case-fatality rate/mortality rate of [disease name] is approximately [number range].
Age
- Patients of all age groups may develop [disease name].
- The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
- [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
- [Chronic disease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group].
Race
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- [Disease name] affects men and women equally.
- [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
Developed Countries
Developing Countries
References
- ↑ Andersen HR, Thuesen L, Bagger JP, Vesterlund T, Thomsen PE (1994). "Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome". Lancet. 344 (8936): 1523–8. doi:10.1016/S0140-6736(94)90347-6. PMID 7983951. Retrieved 2009-06-19. Unknown parameter
|month=ignored (help) - ↑ Heldman D, Mulvihill D, Nguyen H; et al. (1990). "True incidence of pacemaker syndrome". Pacing and Clinical Electrophysiology : PACE. 13 (12 Pt 2): 1742–50. doi:10.1111/j.1540-8159.1990.tb06883.x. PMID 1704534. Unknown parameter
|month=ignored (help);|access-date=requires|url=(help) - ↑ 3.0 3.1 Farmer DM, Estes NA, Link MS (2004). "New concepts in pacemaker syndrome". Indian Pacing and Electrophysiology Journal. 4 (4): 195–200. PMC 1502063. PMID 16943933. Retrieved 2009-06-19.